Cell signaling

Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress

Retrieved on: 
Wednesday, June 3, 2020

ATI-450 is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor in Phase 2 clinical development.

Key Points: 
  • ATI-450 is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor in Phase 2 clinical development.
  • This mechanism leads to the inhibition of multiple cytokines, chemokines, matrix metalloproteases and other inflammatory signals.
  • Key inflammatory cytokines driven by this mechanism include tumor necrosis factor (TNF) and interleukin-1, -1, -6 and -8 (IL1, IL1, IL6 and IL8).
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Angion to Present Results from Multiple Preclinical and Health Economic Studies at the American Transplant Congress Virtual Meeting

Retrieved on: 
Friday, May 29, 2020

ANG-3777 has demonstrated several similarities to HGF, including c-Met dependence and selective c-Met receptor activation, without acting on other growth factor receptors.

Key Points: 
  • ANG-3777 has demonstrated several similarities to HGF, including c-Met dependence and selective c-Met receptor activation, without acting on other growth factor receptors.
  • Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.
  • ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass.
  • Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach.

Sol-Gel to Present at Upcoming Healthcare Investor Conferences

Retrieved on: 
Wednesday, May 27, 2020

Sol-Gels senior management team will provide an overview of the Company and give a business update.

Key Points: 
  • Sol-Gels senior management team will provide an overview of the Company and give a business update.
  • Live webcasts of the presentations will be available under the Events and Presentations in the investors section of the Companys website at www.sol-gel.com .
  • An archived webcast recording of the events will be available on the website for approximately 30 days post presentation.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctatepalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020

Retrieved on: 
Thursday, May 21, 2020

The following virtual oral abstract presentations will be available starting on June 6, 2020.

Key Points: 
  • The following virtual oral abstract presentations will be available starting on June 6, 2020.
  • Allakos is a late-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases.
  • Antolimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils.
  • Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs.

Octant Launches Polypharmacology Drug Discovery Engine for Complex Diseases with $30 Million Series A Financing Led by Andreessen Horowitz

Retrieved on: 
Wednesday, May 20, 2020

Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised $30 million in a Series A financing led by venture capital firm Andreessen Horowitz.

Key Points: 
  • Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised $30 million in a Series A financing led by venture capital firm Andreessen Horowitz.
  • We formed Octant to transform the treatment of societys most complex diseases, for example metabolic and neurological diseases, which involve many protein receptors and receptor pathways.
  • Octant is a synthetic-biology drug discovery company designing multi-target drug leads for multifactorial diseases.
  • Octants novel polypharmacology discovery engine generates multi-receptor pathway data and predictive insights to inform rational drug design with unprecedented speed, scale and precision.

Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Retrieved on: 
Tuesday, May 19, 2020

Additional details on the planned call will be provided in advance of the AACR Virtual Annual Meeting II.

Key Points: 
  • Additional details on the planned call will be provided in advance of the AACR Virtual Annual Meeting II.
  • Revolution Medicines is a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive high-value frontier cancer targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways.
  • Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Revolution Medicines planned R&D update.
  • Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 [email protected] For Media: Vida Strategic Partners Tim Brons 415-675-7402 [email protected]

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results

Retrieved on: 
Wednesday, May 6, 2020

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.

InventHelp Presents Wearable Personal Security Alert (SKC-556)

Retrieved on: 
Tuesday, May 5, 2020

The patent-pending PASS provides a way to quickly and effectively assist victims in signaling life, location and/or need for help.

Key Points: 
  • The patent-pending PASS provides a way to quickly and effectively assist victims in signaling life, location and/or need for help.
  • Created to secure personal safety in dire circumstances, the PASS units greatest features are an inconspicuous design and discreet activation.
  • The original design was submitted to the National sales office of InventHelp.
  • 18-SKC-556, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration

Retrieved on: 
Monday, May 4, 2020

These abstracts were originally accepted for presentation during the 2020 DDW Conference which was to be held May 2-5 in Chicago, IL.

Key Points: 
  • These abstracts were originally accepted for presentation during the 2020 DDW Conference which was to be held May 2-5 in Chicago, IL.
  • Both abstracts describe pre-clinical results with a liver-targeted proprietary molecule that enhances Wnt signaling and stimulates tissue regeneration.
  • SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity) are antibody-based molecules that enhance Wnt signaling.
  • Surrozen Wnt-mimetics, also referred to as SWAP (SurrozenWnt signalActivatingProteins), are bi-specific full-length human (IgG) antibodies that directly activate the canonical Wnt signaling pathway in target tissue.

Berkeley Lights Launches Two New Capabilities in the Opto Cell Therapy Development 1.0 Workflow to Accelerate the Creation Of Effective Cancer Immunotherapies

Retrieved on: 
Monday, April 27, 2020

EMERYVILLE, Calif., April 27, 2020 /PRNewswire/ --Today, Berkeley Lights, Inc., a leader in Digital Cell Biology, launched new capabilities to empower the Opto Cell Therapy Development 1.0 workflow.

Key Points: 
  • EMERYVILLE, Calif., April 27, 2020 /PRNewswire/ --Today, Berkeley Lights, Inc., a leader in Digital Cell Biology, launched new capabilities to empower the Opto Cell Therapy Development 1.0 workflow.
  • Current techniques to assess T cell function don't allow scientists to collect all of the required data from the same cell.
  • The Opto Cell Therapy Development 1.0 workflow enables CAR-T cell phenotypic and functional screening, and the discovery of T cell receptors (TCRs) associated with specific T cell behaviors.
  • Berkeley Lights will continue to release more cell therapy related capabilities to the Berkeley Lights platform in the coming months.